Indeed, brentuximab vedotin is highly active in patients with relapsed/refractory CD30+ ALCL but has less activity against other PTCL subtypes [15, 16]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.